作者
Antje Krohn, Tobias Diedler, Lia Burkhardt, Pascale-Sophie Mayer, Colin De Silva, Marie Meyer-Kornblum, Darja Kötschau, Pierre Tennstedt, Joseph Huang, Clarissa Gerhäuser, Malte Mader, Stefan Kurtz, Hüseyin Sirma, Fred Saad, Thomas Steuber, Markus Graefen, Christoph Plass, Guido Sauter, Ronald Simon, Sarah Minner, Thorsten Schlomm
发表日期
2012/8/1
期刊
The American journal of pathology
卷号
181
期号
2
页码范围
401-412
出版商
Elsevier
简介
The phosphatase and tensin homolog deleted on chromosome 10 (PTEN) gene is often altered in prostate cancer. To determine the prevalence and clinical significance of the different mechanisms of PTEN inactivation, we analyzed PTEN deletions in TMAs containing 4699 hormone-naïve and 57 hormone-refractory prostate cancers using fluorescence in situ hybridization analysis. PTEN mutations and methylation were analyzed in subsets of 149 and 34 tumors, respectively. PTEN deletions were present in 20.2% (458/2266) of prostate cancers, including 8.1% heterozygous and 12.1% homozygous deletions, and were linked to advanced tumor stage (P < 0.0001), high Gleason grade (P < 0.0001), presence of lymph node metastasis (P = 0.0002), hormone-refractory disease (P < 0.0001), presence of ERG gene fusion (P < 0.0001), and nuclear p53 accumulation (P < 0.0001). PTEN deletions were also associated …
引用总数
2012201320142015201620172018201920202021202220232024229334944464034472020127